Enteropathy with impaired membrane digestion and the prospects for cytoprotective therapy

Abstract

The article describes enteropathy with impaired membrane digestion (EIMD) as a new nosological form. The main clinical manifestation of EIMD is the poor tolerance of food products, in particular carbohydrates and a decrease in the activity of membrane enzymes, in particular, carbohydrates, in the mucous membrane of the small intestine. The cause of the disease can be acute intestinal infections, viruses, drugs and other agents that damage the small intestine. The pathophysiology, clinical picture and diagnosis of EIMD are described. The basis of therapy is rebamipide, which has the ability to reduce the symptoms of carbohydrate intolerance and increase the activity of disaccharidases.

Keywords

• membrane digestion
• enteropathy with impaired membrane digestion
• disaccharidase
• peptidase
• disaccharidase deficiency
• diagnosis
• treatment
• rebamipid